RxDoctor Payments Data

Seth Stambaugh, DO

Family Medicine · Durant, OKNPI 1730706219

Payments from drug & device makers

$708in general payments, 2019–2025

Across 39 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$110
  • AbbVie$103
  • Novo Nordisk$80
  • GSK$67
  • Lilly USA, LLC$53
  • Amgen$52
  • plus $243 from 10 others

What the payments were for

  • Food & beverage$708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$708 in reported general payments places this provider in the 55th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$44,754
Medicare patients
221
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab12$81,739
Abilify MaintenaAripiprazole28$77,249
MounjaroTirzepatide67$71,728
Invega SustennaPaliperidone Palmitate15$55,423
OzempicSemaglutide54$51,098
EliquisApixaban61$42,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$41,898
VraylarCariprazine Hcl22$33,386
JardianceEmpagliflozin40$30,400
RexultiBrexpiprazole13$19,154
TrulicityDulaglutide16$15,191
EntrestoSacubitril/Valsartan18$13,827
JanuviaSitagliptin Phosphate17$12,690
RybelsusSemaglutide11$10,550
FarxigaDapagliflozin Propanediol12$8,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Vraylar$103$115,12534 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$110$96,40341 claims
Lilly USA, LLCMounjaro, Trulicity$53$86,91983 claims
Novo NordiskOzempic, Rybelsus$80$61,64865 claims
GSKTrelegy Ellipta$67$41,89860 claims
MerckJanuvia, Janumet$12$18,88828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Durant

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →